Prevalence of Osteoporosis in Sickle Cell Disease

Hospices Civils de Lyon142 enrolled

Overview

Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases. This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France

Study Type

OBSERVATIONAL

Enrollment

142

Conditions

Sickle Cell Disease

Interventions

QuestionnaireOTHER

For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Black-skinned men and women * Aged 20 to 40 years old * Sickle cell patients * Non-opposition to participate in the study Exclusion Criteria: * Refusal to participate in the study * Hemoglobinopathy other than sickle cell disease * Severe or End Stage Renal Failure * Long-term corticosteroid therapy (\>3 months) * History of solid cancer or malignant haemopathy * History of organ transplantation * Pregnant or breastfeeding woman * Psychiatric pathology seriously impeding understanding * Difficulty understanding oral French

Outcomes

Primary Outcomes

Bone mineral density

Bone mineral density is measured by systematic bone densitometry at 3 sites: lumbar spine, femoral neck and total hip. These data will be collected in the patient's medical record

Time frame: Day 1